Weco Biotech consists of:

Y-mAbs Therapeutics, Inc (YmAbs)
That develops novel antibody therapeutics for oncology targets based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center (“MSK”) under an exclusive worldwide license and research collaboration agreement.

YmAbs applies its world-class antibody capabilities to create life-changing immunotherapies for cancer patients of all ages. YmAbs’ innovative product candidates leverage its extensive drug development capabilities and its proprietary protein technology platform – MULTI TAG™.

Y-MABS Denmark

Y-mAbs Therapeutics A/S
Agern Allé 11, ground floor
2970 Hoersholm, Denmark

Phone +45 70 26 14 14
Email info@ymabs.com
Web www.ymabs.com


Y-mAbs Therapeutics Inc
230 Park Avenue, Suite 3350
New York, NY 10169, USA

Phone +1 212 847 9841
Email info@ymabs.com
Web www.ymabs.com